EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriers

Yael Laitman, Karin Aharon, Talia Schloss, Libby Margolin, Eitan Friedman

Familial Cancer · 13.05.2026 · 25 (2)

DOI: 10.1007/s10689-026-00568-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Familial Cancer, online erschienen am 13.05.2026. Verfasst von Yael Laitman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oncogenetics Service, Assuta Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Breast Neoplasms, Prophylactic Mastectomy, BRCA1 Protein, BRCA2 Protein. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Women harboring pathogenic variant (PV) in the BRCA1 or BRCA2 genes (= BRCA ) have an elevated lifetime risk for breast cancer (BC). One of the main options for active BC risk reduction is bilateral risk-reducing mastectomy (RRM). Understanding the factors influencing that decision is important for genetic-counselling and risk mitigation strategy planning. A structured questionnaire was circulated to BRCA carriers, members of the Good Genes NGO in Israel. Data on RRM uptake and timing, factors previously reported to be associated with decision to undergo RRM (e.g., psychosocial, family history, counselling/health-system factors) were obtained. Comparison between carriers who elected to undergo RRM with those who opted for early detection schemes were performed using logistic regression and chi square statistical analyses. Of cancer free women ( n = 391), 272 (69.6%) elected to adhere to the recommended surveillance scheme and 119 (30.4%) elected to undergo RRM. The major reasons for electing RRM over surveillance were active BC risk reduction (4.96 ± 0.23), fear of developing BC (4.86 ± 0.50), and having at least one relative with BC diagnosed under age 45 years. Support group discussions emerged as a stronger determinant of RRM uptake than primary care physician or religious guidance. In conclusion, among healthy Israeli BRCA carriers the decision to undergo RRM was influenced by a complex interplay of factors—active BC risk reduction, fear of cancer diagnosis in the context of having one relative with early onset BC and support group discussions were the major drivers of RRM in Israeli BRCA1 carriers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProphylactic MastectomyBRCA1 ProteinBRCA2 ProteinMastectomyHumansFemaleIsraelMiddle AgedAdultHeterozygoteGenetic Predisposition to DiseaseSurveys and QuestionnairesGenetic CounselingRisk Reduction BehaviorGenes, BRCA1

Stichwörter der Autor:innen

BRCA pathogenic variant carriersBreast cancer riskRisk reducing mastectomySurveillance decisions

Substanzen

BRCA1 protein, humanBRCA2 protein, humanBRCA1 ProteinBRCA2 Protein

Autor:innen und Institutionen

  • Oncogenetics Service, Assuta Medical Center, Tel Aviv, Israel.
  • Good Genes NGO, Nahariya, Israel.
  • Oncogenetics Service, Assuta Medical Center, Tel Aviv, Israel. feitan@tauex.tau.ac.il.
  • The Gray Faculty of Medicine and Health Sciences, Tel-Aviv University, Tel Aviv, Israel. feitan@tauex.tau.ac.il.

Förderung

  • Tel Aviv University

Zitieren

APA

Laitman, Y., Aharon, K., Schloss, T., Margolin, L., & Friedman, E. (2026). Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriers. Familial Cancer, 25(2). https://doi.org/10.1007/s10689-026-00568-x

Vancouver

Laitman Y, Aharon K, Schloss T, Margolin L, Friedman E. Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriers. Familial Cancer. 2026;25(2). doi:10.1007/s10689-026-00568-x

BibTeX
@article{Laitman2026,
  author = {Laitman, Yael and Aharon, Karin and Schloss, Talia and Margolin, Libby and Friedman, Eitan},
  title = {Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriers},
  journal = {Familial Cancer},
  year = {2026},
  volume = {25},
  number = {2},
  doi = {10.1007/s10689-026-00568-x}
}
Kostenlos starten →